The Pattern of Microorganisms and Drug Susceptibility in Pediatric Oncologic Patients with Febrile Neutropenia

被引:6
|
作者
Jungrungrueng, Thanyathorn [1 ]
Anugulruengkitt, Suvaporn [2 ]
Lauhasurayotin, Supanun [3 ]
Chiengthong, Kanhatai [3 ]
Poparn, Hansamon [3 ]
Sosothikul, Darintr [3 ]
Techavichit, Piti [3 ]
机构
[1] Chulalongkorn Univ, Dept Pediat, Fac Med, Bangkok, Thailand
[2] Chulalongkorn Univ, Div Pediat Infect Dis, Dept Pediat, Fac Med, Bangkok, Thailand
[3] Chulalongkorn Univ, Dept Pediat, STAR Clin Res Holist Management Pediat Hematol &, Fac Med, Bangkok, Thailand
关键词
D O I
10.1155/2021/6692827
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Objective. The study aimed to describe the pattern of causative microorganisms, drug susceptibility, risk factors of antibiotic-resistant bacterial infection, and clinical impact of these organisms on pediatric oncology patients with febrile neutropenia. Methods. A retrospective descriptive study of oncologic patients aged less than 15 years who were diagnosed with febrile neutropenia in King Chulalongkorn Memorial Hospital was conducted between January 2013 to December 2017. Characteristics and clinical outcomes of febrile neutropenia episodes, causative pathogens, and their antibiotic susceptibilities were recorded. Result. This study included 267 patients with 563 febrile neutropenia episodes. The median (range) age was 5.1 years (1 month-15 years). The most common underlying disease was acute lymphoblastic leukemia (42.7%). Of 563 febrile episodes, there were 192 (34.1%) with microbiologically documented infection. Among these 192 episodes of microbiologically documented infection, there were 214 causative pathogens: 154 bacteria (72%), 32 viruses (15%), 27 fungus (12.6%), and 1 Mycobacterium tuberculosis (0.4%). Gram-negative bacteria (48.6%) accounted for most of the causative pathogens. Twenty-three percent of them were multidrug resistant, and 18% were carbapenem resistant. Among Gram-positive bacterial infection which accounted for 23.4% of all specimens, the proportion of MRSA was 20%. The 2-week mortality rate was 3.7%. Drug-resistant Gram-negative bacterial infection caused significant adverse events and mortality compared to nonresistant bacterial infection (p<0.05). Conclusion. There is high rate of drug-resistant organism infection in pediatric oncology patients in a tertiary-care center in Thailand. Infection with drug-resistant Gram-negative bacterial infection was associated with significant morbidity and mortality. Continuous surveillance for the pattern of drug-resistant infections is crucial.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] The Pattern of Microorganisms and Drug Susceptibility in Pediatric Oncologic Patients With Febrile Neutropenia
    Techavichit, P.
    Jungrungrueng, T.
    Anugulruengkitt, S.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S284 - S284
  • [2] Yeast Colonization and Drug Susceptibility Pattern in the Pediatric Patients With Neutropenia
    Haddadi, Pedram
    Zareifar, Soheila
    Badiee, Parisa
    Alborzi, Abdolvahab
    Mokhtari, Maral
    Zomorodian, Kamiar
    Pakshir, Keyvan
    Jafarian, Hadis
    JUNDISHAPUR JOURNAL OF MICROBIOLOGY, 2014, 7 (09)
  • [3] Presepsin and Midregional Proadrenomedullin in Pediatric Oncologic Patients with Febrile Neutropenia
    Agnello, Luisa
    Bivona, Giulia
    Parisi, Elisa
    Lucido, Giuseppe Dejan
    Iacona, Alessandro
    Ciaccio, Anna Maria
    Giglio, Rosaria Vincenza
    Ziino, Ottavio
    Ciaccio, Marcello
    LABORATORY MEDICINE, 2020, 51 (06) : 585 - 591
  • [4] Predictive Factors of Severe Adverse Events in Pediatric Oncologic Patients With Febrile Neutropenia
    Techavichit, P.
    Thangthong, J.
    Anugulruengkitt, S.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S160 - S161
  • [5] Microbiological characterization and antimicrobial susceptibility pattern of infections associated with febrile neutropenia in pediatric hemato-oncological patients
    Bello-Suarez, A. K.
    Cuesta-Armesto, M. H.
    Diaz-Rojas, M. J.
    Mendoza-Uribe, Leidy
    Sarmiento-Wilches, P. E.
    ANDES PEDIATRICA, 2022, 93 (01): : 65 - 77
  • [6] Outcome of Oncologic Pediatric Patients Presenting with Febrile Neutropenia after Implementation of the Standard of Procedure in the Outpatient Department
    Malvestiti, Stefano
    Strahm, Brigitte
    Flotho, Christian
    Hettmer, Simone
    Hufnagel, Markus
    Feuchtinger, Tobias
    Niemeyer, Charlotte Marie
    Puzik, Alexander
    BLOOD, 2024, 144
  • [7] PATTERN OF CARE OF FEBRILE NEUTROPENIA PATIENTS IN INDIA
    Prabhash, K.
    Vora, A.
    Nair, R.
    Parikh, P. M.
    ANNALS OF ONCOLOGY, 2008, 19 : 283 - 283
  • [8] Time to Antibiotics in Pediatric Febrile Neutropenia Patients
    Khan, S.
    Ali, A.
    Sana, S.
    Zia, R.
    Baqari, S.
    Wali, R.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S62 - S62
  • [9] Febrile neutropenia in pediatric and adolescent cancer patients
    Bochennek, K.
    Simon, A.
    Laws, H. -J.
    Groll, A. H.
    Lehrnbecher, T.
    MONATSSCHRIFT KINDERHEILKUNDE, 2021, 169 (05) : 443 - 450
  • [10] Gentamicin Pharmacokinetics and Monitoring in Pediatric Patients with Febrile Neutropenia
    Bialkowski, Sabina
    Staatz, Christine E.
    Clark, Julia
    Lawson, Rachael
    Hennig, Stefanie
    THERAPEUTIC DRUG MONITORING, 2016, 38 (06) : 693 - 698